|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kobayashi H, Yamada Y, Sado T, Sakata M,
Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y,
et al: A randomized study of screening for ovarian cancer: A
multicenter study in Japan. Int J Gynecol Cancer. 18:414–420. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buys SS, Partridge E, Black A, Johnson CC,
Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B,
et al: Effect of screening on ovarian cancer mortality: The
Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening
randomized controlled trial. JAMA. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote IB, Witteveen P,
Bamias A, et al: AURELIA: A randomized phase III trial evaluating
bevacizumab combined with chemotherapy for platinum-resistant
recurrent ovarian cancer. J Clin Oncol. 30:327s2012. View Article : Google Scholar
|
|
5
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott C, Meier W,
Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in
platinum-sensitive relapsed ovarian cancer. N Engl J Med.
366:1382–1392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ovarian Cancer Research Program of BC and
Cheryl Brown: Ovarian Cancer Outcomes Unit. OVCARE. Research
platforms, 2013. http://www.ovcare.caFeb 6–2014
|
|
7
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fodde R and Brabletz T: Wnt/beta-catenin
signaling in cancer stemness and malignant behavior. Curr Opin Cell
Biol. 19:150–158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Z, Zhao L and Wang Q: Overexpression of
long non-coding RNA HOTTIP increases chemoresistance of
osteosarcoma cell by activating the Wnt/β-catenin pathway. Am J
Transl Res. 8:2385–2393. 2016.PubMed/NCBI
|
|
10
|
Cui Y, Zhang F, Zhu C, Geng L, Tian T and
Liu H: Upregulated lncRNA SNHG1 contributes to progression of
non-small cell lung cancer through inhibition of miR-101-3p and
activation of Wnt/β-catenin signaling pathway. Oncotarget.
8:17785–17794. 2017.PubMed/NCBI
|
|
11
|
Zhao X, Liu Y and Yu S: Long noncoding RNA
AWPPH promotes hepatocellular carcinoma progression through YBX1
and serves as a prognostic biomarker. Biochim Biophys Acta Mol
Basis Dis. 1863:1805–1816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu F, Zhang X, Yu Q, Han G, Diao F, Wu C
and Zhang Y: LncRNA AWPPH inhibits SMAD4 via EZH2 to regulate
bladder cancer progression. J Cell Biochem. 119:4496–4505. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
American Joint Committee on Cancer, .
Ovary[M]//AJCC cancer staging manual. Springer; New York, NY: pp.
pp.275–283. 2002
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fluss R, Faraggi D and Reiser B:
Estimation of the Youden Index and its associated cutoff point.
Biom J. 47:458–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao
H, Zhong Z and Sun J: Comprehensive analysis of lncRNA expression
profiles reveals a novel lncRNA signature to discriminate
nonequivalent outcomes in patients with ovarian cancer. Oncotarget.
7:32433–32448. 2016.PubMed/NCBI
|
|
17
|
Xiu YL, Sun KX, Chen X, Chen S, Zhao Y,
Guo QG and Zong ZH: Upregulation of the lncRNA Meg3 induces
autophagy to inhibit tumorigenesis and progression of epithelial
ovarian carcinoma by regulating activity of ATG3. Oncotarget.
8:31714–31725. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang M, Wang W, Li T, Yu X, Zhu Y, Ding
F, Li D and Yang T: Long noncoding RNA SNHG1 predicts a poor
prognosis and promotes hepatocellular carcinoma tumorigenesis.
Biomed Pharmacother. 80:73–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moore RG, Brown AK, Miller MC, Skates S,
Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P,
Granai CO and Bast RC Jr: The use of multiple novel tumor
biomarkers for the detection of ovarian carcinoma in patients with
a pelvic mass. Gynecol Oncol. 108:402–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grammatikakis I, Panda AC, Abdelmohsen K
and Gorospe M: Long noncoding RNAs(lncRNAs) and the molecular
hallmarks of aging. Aging (Albany NY). 6:992–1009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Qiu M, Xu Y, Li M, Dong G, Mao Q,
Yin R and Xu L: Long noncoding RNA CCAT2 correlates with smoking in
esophageal squamous cell carcinoma. Tumour Biol. 36:5523–5528.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mayfield RD: Emerging roles for ncRNAs in
alcohol use disorders. Alcohol. 60:31–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
